Clinical Trial Update: Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating KAF156 (ganaplacide) with Lumefantrine Solid Dispersion Formulation (LUM-SDF) in children with uncomplicated Plasmodium falciparum mala…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• KAF156 (ganaplacide) (ganaplacide)
• Lumefantrine (Lum-SDF) (lumefantrine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Status: COMPLETED